. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Cancer Treat Rev. 2013 Mar 1;39(7):10.1016/j.ctrv.2013.01.008. doi: 10.1016/j.ctrv.2013.01.008

Table 1.

Inclusion criteria

Population	Men with localized (T1-T2, N0-Nx, M0) and locally advanced (T3-T4, N0- Nx, M0) prostate cancer

Intervention	HFRT, defined as radiation that is delivered as a single 2.1-3.5 Gy fraction lasting about one hour per day, five days per week, for about four weeks

Control	CFRT, defined as a single 1.8-2.0 Gy fraction lasting one hour per day, five days per week, for about eight weeks

Outcomes
Efficacy	Clinical (surrogate outcomes) for all studies: PSA kinetics; FFBF as defined by ASTRO or Phoenix definitions
	Patient and study-specific: DM; LF; LRF; OS; post-treatment biopsy
Safety	Acute and chronic RTOG GU, GI toxicities

Study design
Efficacy	All prospective studies, >50 patients, with two or more arms, >24 month FU
Safety	All prospective studies, >50 patients, with two or more arms, >24 month FU

Abbreviations: ASTRO: American Society of Therapeutic Radiology and Oncology; CFRT: conventionally fractionated radiotherapy; DM: distant metastasis; L/R F: local / regional failure; FFBF: freedom from biochemical failure; FU: follow-up; GI: gastrointestinal; GU: genitourinary; HFRT: hypofractionated radiotherapy; OS: overall survival